Becton, Dickinson and Company reported stronger-than-expected Q1 results for fiscal 2026, driven by disciplined execution and robust growth across key areas, despite challenges in certain segments.
- Revenues reached $5.3 billion, with new segments growing by 2.5% supported by double-digit growth in biologic drug delivery and advanced tissue regeneration.
- Adjusted gross margin improved to 53.4%, and adjusted EPS was $2.91, both exceeding expectations.
- The company is set to close a significant Reverse Morris Trust transaction with Waters, unlocking $4 billion in cash, with plans to allocate $2 billion to share repurchases and $2 billion for debt reduction.
- Enhanced capital allocation strategy emphasizes share buybacks, consistent dividends, and focused M&A to drive return on invested capital.
Community Discussion